AdMeTech Foundation is a nonprofit 501(c)(3) organization dedicated to innovative solutions for improved patient care and transfer of medical research and technologies from laboratories to clinics

Specifically, AdMeTech Foundation is dedicated to research and education for advancement of diagnostic tools to improve early detection and treatment of life-threatening diseases, with prostate cancer as a priority focus and as a model.

AdMeTech has formed strategic partnerships with leaders in medicine, advocacy groups, health care industry, media, communications companies, and government to facilitate development of accurate and affordable prostate cancer diagnostics, including improved in vitro testing (e.g., blood and urinary tests) and imaging tools.

AdMeTech  supports the early stages of high-impact research projects, before other funding entities are prepared to take a risk. At that early stage, the investment is at its lowest and the impact is at its highest.

AdMeTech's priority focus is to end the era of blind prostate cancer care and to create the future of image-guided, precisely-targeted diagnosis and treatment. Prostate cancer is a threat to every man and should be recognized immediately as a national priority comparable to that of breast cancer. This most common major cancer in the United States is curable when detected early, and yet, it is the second most lethal cancer in men and does not have diagnostic tools comparable to life-saving mammograms in women. The lack of accurate and affordable diagnostics causes prostate cancer to become both a patient care crisis and a socio-economic problem, compromising the quality of life and survival in millions of American men and adds billions of dollars to our nation’s health care costs.  Advanced prostate imaging will improve early detection and allow for minimally-invasive alternatives to current treatment, which can be performed in outpatient clinics, with reduced discomfort, complications and costs.

The importance of early diagnosis and treatment of prostate cancer is highlighted by such initiatives in the US Congress as the Prostate Research Imaging and Men’s Education Act (PRIME Act) and House Resolution 353. The PRIME Act calls for government funding of $650 million over 5 years for research and education to advance prostate cancer diagnostics. House Resolution 353 calls for increased government investment in image-guided, minimally-invasive diagnosis and treatment of prostate cancer.